Related references
Note: Only part of the references are listed.Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Lucy C. Riches et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Antje M. Wengner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Fumi Higuchi et al.
CLINICAL CANCER RESEARCH (2020)
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Catherine Hanna et al.
NEURO-ONCOLOGY (2020)
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd et al.
ONCOGENE (2020)
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Paul Lesueur et al.
BMC CANCER (2019)
Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
Amirali B. Bukhari et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Elizabeth Ruth Plummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
Graham MacLeod et al.
CELL REPORTS (2019)
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Bernd Kaina et al.
DNA REPAIR (2019)
DNA-PK as an Emerging Therapeutic Target in Cancer
Ismail S. Mohiuddin et al.
FRONTIERS IN ONCOLOGY (2019)
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S. Kristeleit et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting
Julian Biau et al.
FRONTIERS IN ONCOLOGY (2019)
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Shiv K. Gupta et al.
FRONTIERS IN ONCOLOGY (2019)
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
Pamela Munster et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Nader Sanai et al.
CLINICAL CANCER RESEARCH (2018)
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Jeremy Karlin et al.
MOLECULAR CANCER THERAPEUTICS (2018)
ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
Guido Frosina et al.
RADIATION ONCOLOGY (2018)
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
Stephen T. Durant et al.
SCIENCE ADVANCES (2018)
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Xiaoyue Chen et al.
NATURE COMMUNICATIONS (2018)
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
Kevin M. Foote et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM
Brian Alexander et al.
NEURO-ONCOLOGY (2018)
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Kaiming Sun et al.
Oncotarget (2018)
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
Ben Fulton et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs
Omar L. Kantidze et al.
TRENDS IN CANCER (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Andrew N. Blackford et al.
MOLECULAR CELL (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling
Teodora Nikolova et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Marwan Kwok et al.
BLOOD (2016)
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
Shiv K. Gupta et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
Shiv K. Gupta et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway
Stephanie A. Yazinski et al.
ANNUAL REVIEW OF GENETICS, VOL 50 (2016)
The DNA damage-induced cell death response: a roadmap to kill cancer cells
Sonja Matt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
DNA mismatch repair and the DNA damage response
Zhongdao Li et al.
DNA REPAIR (2016)
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
Sergio Ruiz et al.
MOLECULAR CELL (2016)
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Karolina N. Dziadkowiec et al.
MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY (2016)
Mutational signatures of ionizing radiation in second malignancies
Sam Behjati et al.
NATURE COMMUNICATIONS (2016)
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities (vol 14, pg 298, 2016)
Kumar Sanjiv et al.
CELL REPORTS (2016)
DNA damage and the balance between survival and death in cancer biology
Wynand P. Roos et al.
NATURE REVIEWS CANCER (2016)
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
M. R. Middleton et al.
ANNALS OF ONCOLOGY (2015)
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma
Jenny L. Pokorny et al.
CLINICAL CANCER RESEARCH (2015)
Molecular Pathways: Targeting ATR in Cancer Therapy
Larry M. Karnitz et al.
CLINICAL CANCER RESEARCH (2015)
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Karen E. Parrish et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
A. Bakr et al.
NUCLEIC ACIDS RESEARCH (2015)
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells
Anna-Maria Barciszewska et al.
PLOS ONE (2015)
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
Fiona K. Middleton et al.
ONCOTARGET (2015)
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
Maja T. Tomicic et al.
ONCOTARGET (2015)
A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Daniel L. Menezes et al.
MOLECULAR CANCER RESEARCH (2015)
Tug of War between Survival and Death: Exploring ATM Function in Cancer
Venturina Stagni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
CHK2 kinase in the DNA damage response and beyond
Laura Zannini et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2014)
Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors
Kexiao Guo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Wynand P. Roos et al.
CANCER LETTERS (2013)
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Laura Biddlestone-Thorpe et al.
CLINICAL CANCER RESEARCH (2013)
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
Kevin M. Foote et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
Michael A. Batey et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide
Marcus Eich et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Yosef Shiloh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors
Arina Riabinska et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
Yoshinari Shinsato et al.
ONCOTARGET (2013)
Enhancing CHK1 inhibitor lethality in glioblastoma
Yong Tang et al.
CANCER BIOLOGY & THERAPY (2012)
Combined inhibition of Chk1 and Wee1 In vitro synergistic effect translates to tumor growth inhibition in vivo
Laura Carrassa et al.
CELL CYCLE (2012)
PARP-1 protein expression in glioblastoma multiforme
A. Galia et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2012)
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells
Aditi Nadkarni et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts et al.
CANCER DISCOVERY (2012)
Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
Koji Yoshimoto et al.
FRONTIERS IN ONCOLOGY (2012)
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
A. Peasland et al.
BRITISH JOURNAL OF CANCER (2011)
CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
Victoria E. Anderson et al.
CANCER RESEARCH (2011)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Joerg Felsberg et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
Jean-Damien Charrier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair
Petra Langerak et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
Processing of O-6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles
Steve Quiros et al.
CELL CYCLE (2010)
Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O-6-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs
Wynand P. Roos et al.
DNA REPAIR (2009)
Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
Andrew G. Jobson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Sarah E. Golding et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Mechanism of eukaryotic homologous recombination
Joseph San Filippo et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation
Michael D. Rainey et al.
CANCER RESEARCH (2008)
Homologous recombination in DNA repair and DNA damage tolerance
Xuan Li et al.
CELL RESEARCH (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine
W. P. Roos et al.
ONCOGENE (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
I Hickson et al.
CANCER RESEARCH (2004)
Positive regulation of Wee1 by Chk1 and 14-3-3 proteins
J Lee et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma
F Nomura et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2000)
Share Paper
